Sarabjeet Singh, Meenakshi Verma, Amol Bahekar, Preeti Agrawal, Jasleen Duggal, Maria Iliescu, Pam Khosla, Shirin Muzaffar
Enoxaparin, a low-molecular-weight heparin used to treat and prevent deep venous thrombosis, has been evaluated in several clinical trials. Thrombosis induced by enoxaparin with no evidence of heparin-induced thrombocytopenia (HIT) is seldom described. We report a rare case in which an 89-year-old African-American female developed large, multiple, painful lesions induced by enoxaparin administration. Laboratory investigations for HIT, disseminated intravascular coagulation, protein C, protein S, factor V, factor VIII, antithrombin III, and homocysteine deficiency were negative...
July 2007: American Journal of Therapeutics